Diabetes

Natural product-based therapy for TIIDM: A pharmaceutical mixture encompassing Celastrol, Mangiferin, Fisetin, Spermidine, and Ursolic acid (CMFSU) augments the expression of FGF19 and FGF1,   attenuates hepatic glucose production, decreases hepatic acetyl CoA content, brings down the levels of plasma ACTH, and corticosterone, augments insulin sensitivity, promotes weight loss and alleviates TIIDM via up regulation of its target gene, 13/September/2017, 12.13 am
Natural product-based therapy for TIIDM: A pharmaceutical mixture encompassing Celastrol, Mangiferin, Fisetin, Spermidine, and Ursolic acid (CMFSU) augments the expression of FGF19 and FGF1,   attenuates hepatic glucose production, decreases hepatic acetyl CoA content, brings down the levels of plasma ACTH, and corticosterone, augments insulin sensitivity, promotes weight loss and alleviates TIIDM via up regulation of its target gene, 13/September/2017, 12.13 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from Diabetes and Obesity Center of Excellence, Department of Medicine, University of Washington, Seattle, Washington, USA shows that Central injection of FGF1 induces sustained…

read more

Natural product therapy for Diabetic nephropathy (DN): Artesunate, isolated from Artemisia annua L, increases Pyruvate kinase M2 (PKM2) expression, decreases toxic glucose metabolites, mitochondrial dysfunction and apoptosis, augments glycolytic flux and PGC-1α levels, improves metabolic abnormalities, albuminuria, glomerular pathology, and renal dysfunction and alleviates diabetic nephropathy via down regulation of its target gene, 9/September/2017, 1.24 am
Natural product therapy for Diabetic nephropathy (DN): Artesunate, isolated from Artemisia annua L, increases Pyruvate kinase M2 (PKM2) expression, decreases toxic glucose metabolites, mitochondrial dysfunction and apoptosis, augments glycolytic flux and PGC-1α levels, improves metabolic abnormalities, albuminuria, glomerular pathology, and renal dysfunction and alleviates diabetic nephropathy via down regulation of its target gene, 9/September/2017, 1.24 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Research Division, Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts, USA shows that “Pyruvate kinase M2 activation may protect against the progression…

read more

Natural product therapy for middle aged TIIDM patients: Artesunate, isolated from Artemisia Annua L, decreases DNA-PPK expression, suppresses phosphorylation of HSP90a, increases AMPK activity, augments mitochondrial biogenesis and energy metabolism, promotes weight loss and exercise endurance and alleviates TIIDM via down regulation of its target gene, 8/September/2017, 1.08 am
Natural product therapy for middle aged TIIDM patients: Artesunate, isolated from Artemisia Annua L, decreases DNA-PPK expression, suppresses phosphorylation of HSP90a, increases AMPK activity, augments mitochondrial biogenesis and energy metabolism, promotes weight loss and exercise endurance and alleviates TIIDM via down regulation of its target gene, 8/September/2017, 1.08 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Laboratory of Obesity and Aging Research, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA; and Laboratory…

read more

Molecular therapy for TIIDM and obesity-associated metabolic deficits: Rivaroxaban (Trade name: Xarelto), an anti-coagulant and a blood thinner,  increases Lipocalin 2 (LCN2) expression, activates an MC4R-dependent anorexigenic pathway, suppresses appetite and weight gain, increases insulin secretion, improves glucose tolerance, promotes glucose homeostasis, improves obesity-associated metabolic deficits and prevents progression to TIIDM via down regulation of its target gene, 8/September/2017, 12.32 pm
Molecular therapy for TIIDM and obesity-associated metabolic deficits: Rivaroxaban (Trade name: Xarelto), an anti-coagulant and a blood thinner,  increases Lipocalin 2 (LCN2) expression, activates an MC4R-dependent anorexigenic pathway, suppresses appetite and weight gain, increases insulin secretion, improves glucose tolerance, promotes glucose homeostasis, improves obesity-associated metabolic deficits and prevents progression to TIIDM via down regulation of its target gene, 8/September/2017, 12.32 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Department of Physiology-Cellular Biophysics, College of Physicians and Surgeons, Columbia University, New York, New York, USA shows that “MC4R-dependent suppression of appetite…

read more

Molecular therapy for Metabolic diseases: Rivaroxaban (Trade name: Xarelto), an anticoagulant drug, increases the expression of Caveolin-1, stabilizes insulin receptor, promotes insulin sensitivity, increases vasorelaxation, and decreases the risk of hyperglycemia and TIIDM via up regulation of its target gene., 1/September/2017, 11.51 pm
Molecular therapy for Metabolic diseases: Rivaroxaban (Trade name: Xarelto), an anticoagulant drug, increases the expression of Caveolin-1, stabilizes insulin receptor, promotes insulin sensitivity, increases vasorelaxation, and decreases the risk of hyperglycemia and TIIDM via up regulation of its target gene., 1/September/2017, 11.51 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Institute for Molecular Systems Biology, ETH Zurich, Zurich, Switzerland shows that “MicroRNAs 103 and 107 regulate insulin sensitivity.” This study was published,…

read more

Molecular therapy for TIIDM and obesity-associated metabolic deficits: Ruxolitinib, a drug used in the treatment of Myelofibrosis,  increases Lipocalin 2 (LCN2) expression, activates an MC4R-dependent anorexigenic pathway, suppresses appetite and weight gain, increases insulin secretion, improves glucose tolerance, promotes glucose homeostasis, improves obesity-associated metabolic deficits and prevents progression to TIIDM via down regulation of its target gene, 1/September/2017, 11.28 pm
Molecular therapy for TIIDM and obesity-associated metabolic deficits: Ruxolitinib, a drug used in the treatment of Myelofibrosis,  increases Lipocalin 2 (LCN2) expression, activates an MC4R-dependent anorexigenic pathway, suppresses appetite and weight gain, increases insulin secretion, improves glucose tolerance, promotes glucose homeostasis, improves obesity-associated metabolic deficits and prevents progression to TIIDM via down regulation of its target gene, 1/September/2017, 11.28 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Department of Physiology-Cellular Biophysics, College of Physicians and Surgeons, Columbia University, New York, New York, USA shows that “MC4R-dependent suppression of appetite…

read more
Start Typing